Table 3 Characteristics of interview participants
Participant ID | Role | Trial(s) involved in (subject area), where applicable |
|---|---|---|
01 | TSC Chair | 1, 2 (oncology) |
02* | Project lead | 1, 5 (oncology) |
03 | TSC coordinator #1 | 1, 2 (oncology) |
04 | TSC coordinator #2 | 1, 2 (oncology) |
05* | Sponsor representative | 1, 2 (oncology) |
06* | Sponsor representative | 1, 2 (oncology) |
07* | Trial manager | 1 (oncology) |
08* | CI | 2 (oncology) |
09* | Trial manager | 2 (oncology) |
10* | Trial manager | 3 (arthritis) |
11* | Statistician | 3 (arthritis) |
12* | Trial manager | 3 (arthritis) |
13 | Statistician | 3 (arthritis) |
14 | CI | 3 (arthritis) |
15 | TSC Chair | 3 (arthritis) |
16* | Trial manager | 4 (frailty) |
17 | TSC Chair | 4 (frailty) |
18 | CI | 4 (frailty) |
19 | TMG Chair | 4 (frailty) |
20* | TMG member | 4 (frailty) |
21* | Trial manager | 5 (oncology) |
22 | Statistician | 5 (oncology) |
23* | CI | 5 (oncology) |
24* | Independent TSC member | 5 (oncology) |
25 | Independent TSC member | 5 (oncology) |
26* | Trial manager | 6 (urology) |
27* | Trial manager | 6 (urology) |
28* | Statistician | 6 (urology) |
29* | CI | 6 (urology) |
30* | TSC Chair | 6 (urology) |
31* | Independent TSC member | 6 (urology) |
32* | TMG member | 6 (urology) |
33* | Trial manager | 7 (psychology) |
34* | CI | 7 (psychology) |
35* | Public contributor | 7 (psychology) |
36* | TSC Chair | 7 (psychology) |
37* | Statistician | 7 (psychology) |
38* | TSC Member | 7 (psychology) |
39 | CTU Director | 7 (psychology) |
40* | Trial manager | 7 (psychology) |
41* | Trial manager | 8 (oncology) |
42* | Chair | 8 (oncology) |
43a* | Public contributor | 8 (oncology) |
43b* | Public contributor | 8 (oncology) |
44 | Statistician | 8 (oncology) |
45* | Sponsor representative | 8 (oncology) |
46* | CI of other trial/member of TSCs | n/a |
47* | Funder representative | n/a |
48 | Sponsor representative | n/a |
49* | Funder representative | n/a |
50* | Statistician | n/a |
51* | Funder representative | n/a |